Invention Grant
- Patent Title: Selective hydroxamate based MMP inhibitors
- Patent Title (中): 选择性羟肟酸基MMP抑制剂
-
Application No.: US13469427Application Date: 2012-05-11
-
Publication No.: US08314148B2Publication Date: 2012-11-20
- Inventor: Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin Keaney , Ayako Honda
- Applicant: Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin Keaney , Ayako Honda
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Sophie Binet Cross
- Main IPC: A01N41/06
- IPC: A01N41/06 ; C07C303/00 ; C07D211/70
Abstract:
The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
Public/Granted literature
- US20120225882A1 SELECTIVE HYDROXAMATE BASED MMP INHIBITORS Public/Granted day:2012-09-06
Information query
